July 01, 2025 09:00 ET | Source: Inmagene Biopharmaceuticals The ADAPTIVE Phase 2b trial evaluates multiple dose regimens of IMG-007…
Accelmed $20 Million Investment with 3E Bioventures Capital Funding of $3 Million to Drive Innovation, Clinical Expansion, and Global Market…
New solution improves protocol design, reduces patient- and site-burden, accelerates recruitment, and delivers increased efficiencies for clinical trials SINGAPORE, June…